Evidence map›Paper›PMID 39859312›Full record

ArticleInternational journal of molecular sciences2025

Structure-Based Discovery of MolPort-137: A Novel Autotaxin Inhibitor That Improves Paclitaxel Efficacy.

Prateek Rai, Christopher J Clark, Vandana Kardam, Carl B Womack, Joshua Thammathong, Derek D Norman, Gábor J Tigyi, Kevin Bicker, April M Weissmiller, Kshatresh Dutta Dubey and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Prateek RaiMolecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.ORCID 0000-0002-3887-2694
Christopher J ClarkMolecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
Vandana KardamDepartment of Chemistry, Shiv Nadar Institution of Eminence, Delhi 201314, India.
Carl B WomackDepartment of Biology, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
Joshua ThammathongDepartment of Chemistry, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
Derek D NormanDepartment of Physiology, University of Tennessee Health Science Center, Memphis, TN 37132, USA.
Gábor J TigyiDepartment of Physiology, University of Tennessee Health Science Center, Memphis, TN 37132, USA.ORCID 0000-0001-5371-171X
Kevin BickerMolecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.
April M WeissmillerMolecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.ORCID 0000-0003-4505-0530
Kshatresh Dutta DubeyDepartment of Chemistry, Shiv Nadar Institution of Eminence, Delhi 201314, India.ORCID 0000-0001-8865-7602
Souvik BanerjeeMolecular Biosciences, Middle Tennessee State University, Murfreesboro, TN 37132, USA.ORCID 0000-0002-7811-2577

Funding

Middle Tennessee State University Startup Funding 210268Wellcome Trust 220000
6 · The paper itself

Abstract

The autotaxin-lysophosphatidic acid receptor (ATX-LPAR) signaling axis is pivotal in various clinical conditions, including cancer and autoimmune disorders. This axis promotes tumorigenicity by interacting with the tumor microenvironment, facilitating metastasis, and conceding antitumor immunity, thereby fostering resistance to conventional cancer therapies. Recent studies highlight the promise of ATX/LPAR inhibitors in combination with conventional chemotherapeutic drugs to overcome some forms of this resistance, representing a novel therapeutic strategy. In the current study, we employed structure-based virtual screening, integrating pharmacophore modeling and molecular docking, to identify MolPort-137 as a novel ATX inhibitor with an IC

Indexed as

PaclitaxelPhosphoric Diester HydrolasesAnimalsCell Line, TumorDrug DiscoveryDrug Resistance, NeoplasmFemaleHumansLysophospholipase DMiceMolecular Docking SimulationMolecular Dynamics SimulationReceptors, Lysophosphatidic AcidLysophospholipase DPaclitaxelPhosphoric Diester HydrolasesReceptors, Lysophosphatidic Acidautotaxincancer therapy resistancecombination therapyLPA signalingmolecular simulationsvirtual screening

Identifiers

PMID39859312
PMCPMC11765394

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.